updated 3/8/2011 9:16:55 AM ET 2011-03-08T14:16:55

BEIJING, March 8, 2011 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced it has appointed Mr. Tao Zhu as the Company's Executive Vice President of Sales and Marketing, effective immediately.

Mr. Zhu has nearly 15 years of experience in the pharmaceutical industry, with a proven track record of leadership and performance. He began his pharmaceutical career as a sales representative and, over the years, assumed an increasing amount of responsibilities in sales and marketing efforts at several leading companies. Mr. Zhu joined Nuokang in July of 2009, as the Head of Marketing Agent Management for the Company's Baquting product. Under Mr. Zhu's management, Baquting's sales via agent channels achieved a significant growth. Previously, he was the North China commercial manager for Bayer HealthCare AG and the North China regional manager for Topsun Pharmaceutical Co. Mr. Zhu has an Executive MBA from Renmin University and a Bachelor degree from Dalian Medical University.

Mr. Zhu replaces Mr. Lijun Zhang, who had served as the Vice President of Sales and Marketing at the Company since December 2006.

Mr. Baizhong Xue, the Company's Chairman and Chief Executive Officer, stated, "We would like to thank Mr. Zhang for his contributions to Nuokang's sales and marketing team. We are pleased with his accomplishments and are confident that Mr. Zhu will continue in his footsteps to further strengthen our sales and marketing efforts. Since joining our firm in 2009, Mr. Zhu has played an important role in achieving the success we have had with Baquting and we believe he is well-suited for his expanded role as he leads the successful commercialization of our pipeline products going forward."

About China Nuokang Bio-Pharmaceutical Inc.

China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hospital-based medical products. The Company provides a diversified portfolio of products across more than 2,400 hospitals in China. Nuokang's principal products include Baquting®, China's leading hemocoagulase product by market share, and Aiduo®, a cardiovascular stress imaging agent. The Company's product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. Please visit www.nkbp.com for more information.  

Safe-Harbor Statement

This press release contains statements of a forward-looking nature. These statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including certain plans, expectations, goals, and projections, which are subject to numerous assumptions, risks, and uncertainties. These forward-looking statements may include, but are not limited to, statements containing words such as "may," "could," "would," "plan," "anticipate," "believe," "estimate," "predict," "potential," "expects," "intends" and "future" or similar expressions. Among other things, the statements relating to the Company's expected progress on the new product portfolio may contain forward-looking statements. These forward-looking statements speak only as of the date of this press release and are subject to change at any time. These forward-looking statements are based upon management's current expectations and are subject to a number of risks, uncertainties and contingencies, many of which are beyond the Company's control that may cause actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. The Company's actual results could differ materially from those contained in the forward-looking statements due to a number of factors, including those described under the heading "Risk Factors" in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F.

CONTACT: ICR, LLC
         In the U.S.:
         Ashley M. Ammon
         1-646-277-1227

         In China: 
         Wen Lei Zheng
         86-10-6583-7510

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.94%
$30K home equity loan FICO 5.19%
$75K home equity loan FICO 4.58%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.40%
13.40%
Cash Back Cards 17.92%
17.91%
Rewards Cards 17.12%
17.11%
Source: Bankrate.com